netFormulary NHS
Cambridgeshire and Peterborough
Formulary
 Search
 Results

Looking for Apixaban found 15 matches

Formulary BNF Category
  Restricted Drug  Apixaban  (Eliquis) Oral anticoagulants - 02.08.02
 
Non Formulary BNF Category
  Andexanet alfa  (Ondexxya) Anticoagulants and protamine - 02.08


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in subsection CUH Management of bleeding in patients on direct oral anticoagulants (DOACs): dabigatran, rivaroxaban, apixaban and edoxaban (02.08.02)
link in subsection CUH Oral Anticoagulant Therapy Counselling Checklist For Oral Direct Inhibitors (ODI) Dabigatran / Rivaroxaban / Apixaban (02.08.02)
link in subsection MHRA Advice: New oral anticoagulants apixaban (Eliquis), dabigatran (Pradaxa) and rivaroxaban (Xarelto) - Risk of serious haemorrhage (02.08.02)
link in drug section MHRA Drug Safety Update December 2014: New oral anticoagulants apixaban (Eliquis▼), dabigatran (Pradaxa) and rivaroxaban (Xarelto▼) - Risk of serious haemorrhage and clarified contraindications apply to all 3 medicines. (02.08.02)
link in drug section MHRA Drug Safety Update December 2014: New oral anticoagulants apixaban (Eliquis▼), dabigatran (Pradaxa) and rivaroxaban (Xarelto▼) - Risk of serious haemorrhage and clarified contraindications apply to all 3 medicines. (02.08.02)
link in drug section MHRA Drug Safety Update December 2014: New oral anticoagulants apixaban (Eliquis▼), dabigatran (Pradaxa) and rivaroxaban (Xarelto▼) - Risk of serious haemorrhage and clarified contraindications apply to all 3 medicines. (02.08.02)
link in drug section MHRA Letters sent to healthcare professionals in May 2019: Apixaban (Eliquis), dabigatran etexilate (Pradaxa), edoxaban (Lixiana▼) and rivaroxaban (Xarelto▼) are not recommended in patients with antiphospholipid syndrome (02.08.02)
link in drug section MHRA Letters sent to healthcare professionals in May 2019: Apixaban (Eliquis), dabigatran etexilate (Pradaxa), edoxaban (Lixiana▼) and rivaroxaban (Xarelto▼) are not recommended in patients with antiphospholipid syndrome  (02.08.02)
link in drug section MHRA Letters sent to healthcare professionals in May 2019: Apixaban (Eliquis), dabigatran etexilate (Pradaxa), edoxaban (Lixiana▼) and rivaroxaban (Xarelto▼) are not recommended in patients with antiphospholipid syndrome (02.08.02)
link in drug section MHRA Letters sent to healthcare professionals in May 2019: Apixaban (Eliquis), dabigatran etexilate (Pradaxa), edoxaban (Lixiana▼) and rivaroxaban (Xarelto▼) are not recommended in patients with antiphospholipid syndrome (02.08.02)
link in drug section NICE TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (02.08.02)
link in drug section NICE TA275: Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (02.08.02)
link in drug section NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (02.08.02)


 

netFormulary